Doxorubicin liposomal - Innomedica

Drug Profile

Doxorubicin liposomal - Innomedica

Alternative Names: Talidox; Targeted liposomal doxorubicin; TLD; TLD-1

Latest Information Update: 18 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator InnoMedica
  • Developer InnoMedica; Mario Negri Institute for Pharmacological Research
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 11 May 2017 Chemical structure information added
  • 25 Apr 2017 Innomedica and Swiss Association for Clinical Cancer Research (SAKK) plan a phase IIb/III trial for Solid tumours in Switzerland
  • 25 Apr 2017 Innomedica and Swiss Association for Clinical Cancer Research (SAKK) plan a dose escalation phase I trial for Solid tumours in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top